Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time.

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The move will start nationwide in mid-November and will have direct-to-consumer pricing through LillyDirect.

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.